MedTrace Logo

A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

NCT03032107 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-01-27

Study results available
· View outcomes & findings →

Summary

This research study is studying a combination of drugs as a possible treatment for metastatic breast cancer.

The interventions involved in this study are:

* Pembrolizumab
* Trastuzumab emtansine (also called T-DM1)

Conditions

Interventions

DRUG

T-DM1

-T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle

DRUG

Pembrolizumab

-Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle

Sponsors & Collaborators

Principal Investigators

  • Sara Tolaney, MD MPH · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-17
Primary Completion
2020-10-29
Completion
2024-12-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03032107 on ClinicalTrials.gov